Log in

BioSyent Stock Forecast, Price & News

0.00 (0.00 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $5.49
50-Day Range
MA: $5.31
52-Week Range
Now: $5.49
Average Volume5,710 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells and is indicated for the prevention of iron deficiency anemia; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains. BioSyent Inc. sells its products number of wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Phone905 206 0013



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIOYF News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOYF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioSyent (OTCMKTS:BIOYF) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of BioSyent?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSyent in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for BioSyent
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BioSyent?

Wall Street analysts have given BioSyent a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioSyent wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for BIOYF?

1 analysts have issued twelve-month target prices for BioSyent's stock. Their forecasts range from $7.00 to $7.00. On average, they expect BioSyent's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price.
View analysts' price targets for BioSyent

Are investors shorting BioSyent?

BioSyent saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 3,500 shares, an increase of 75.0% from the October 15th total of 2,000 shares. Based on an average daily volume of 3,100 shares, the short-interest ratio is currently 1.1 days.
View BioSyent's Short Interest

Who are some of BioSyent's key competitors?

Who are BioSyent's key executives?

BioSyent's management team includes the following people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Robert J. March, VP of Fin. & CFO
  • Mr. Joost van der Mark, VP of Corp. Devel.
  • Ms. Neelu Atwal, Director of HR
  • Mr. Alfred D'Souza, Advisor

What is BioSyent's stock symbol?

BioSyent trades on the OTCMKTS under the ticker symbol "BIOYF."

How do I buy shares of BioSyent?

Shares of BIOYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioSyent's stock price today?

One share of BIOYF stock can currently be purchased for approximately $5.49.

What is BioSyent's official website?

The official website for BioSyent is www.biosyent.com.

How can I contact BioSyent?

The company can be reached via phone at 905 206 0013.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.